Shares of Guardian Pharmacy Services, Inc. (GRDN) surged 6.03% in pre-market trading on Thursday following the release of its impressive fourth-quarter and full-year 2024 financial results, coupled with an optimistic outlook for 2025.

Guardian Pharmacy Services, a leading long-term care pharmacy provider specializing in assisted living and memory care facilities, reported robust growth across key metrics. For the fourth quarter of 2024, the company achieved revenue of $339 million, marking a 20% year-over-year increase. The full-year 2024 revenue reached $1.228 billion, up 17% compared to the previous year. Notably, the company's adjusted EBITDA for Q4 grew by 30% to $26 million, while the full-year adjusted EBITDA rose 19% to $91 million.

Looking ahead, Guardian Pharmacy Services provided a strong guidance for 2025, projecting revenue between $1.33 billion and $1.35 billion, and adjusted EBITDA ranging from $97 million to $101 million. The company's growth strategy includes organic expansion, greenfield startups, and strategic acquisitions, with a focus on maintaining its market leadership in the assisted living and behavioral health sectors.

Analysts have responded positively to Guardian's performance and outlook. David S Macdonald from Truist Financial reiterated a Buy rating on GRDN stock, reflecting confidence in the company's growth trajectory and market position. The company's ability to transform its vaccine administration process from a profitability headwind to a slight tailwind has also been well-received by investors.